GSC
TVRD

Ground Swell Capital’s Tvardi Therapeutics TVRD Stock Holding History

Ground Swell Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Buy
+15
New +$6.16K 0.01% 1485

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ground Swell Capital's TVRD Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Tvardi Therapeutics (TVRD) in Q3 2014: 15 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #1485 among its holdings.

56 funds tracked by Wall St. Rank hold TVRD as of Q3 2014.

  • Ground Swell Capital held 15 shares of Tvardi Therapeutics worth $5K as of Q3 2014.
  • Tvardi Therapeutics was a new Ground Swell Capital position in Q3 2014.
  • Tvardi Therapeutics made up 0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1485 holding.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.